Business
Men in A Meeting
(Getty Images)

IPOs slow? Invent your own private stock market!

Welcome to the startup stock market

I have written, a few times now, about how a slowdown in private equity exits has been putting pressure on funds that need to return capital to their investors, with some funds now loading their companies with debt to help pay for dividends to distribute cash. Venture capital has been facing a similar bottleneck. A sluggish IPO market and a growing number of companies staying private has made it more difficult for VC funds to exit positions and return capital to their investors. But now, some venture funds are providing a solution to the problem by offering to buy shares from other investors at a discount. From The Financial Times:

The venture capital group G Squared has raised $1.1bn for its latest fund to capitalise on growing investor demand for its strategy of buying pre-existing stakes in start-ups.

Founded in 2011 and based in Chicago, G Squared has backed technology groups such as artificial intelligence company Anthropic and cyber security specialist Wiz.

While typical venture capitalists focus on buying new shares in start-ups, G Squared invests most of its funds in existing shares, bought directly from start-up employees and investors who want to sell some of their holdings.

Larry Aschebrook, the founder and managing partner of G Squared, also told the Financial Times that “investors can buy shares in the secondary market at about a 30 per cent discount to company’s value, and at a 70 per cent to 80 per cent discount to the prices investors paid during the low interest rate-fuelled boom times of the coronavirus pandemic.”

In public markets, the price you see is typically the price you get, unless you’re buying or selling a multi-million dollar position. If Apple is trading at $230 per share and you want to buy Apple’s stock, you’re going to pay $230. Tens of millions of Apple shares trade hands each day, and they are easy to buy and sell.

In the private markets, however, the price you get is what someone is willing to pay. And the cost of liquidity is, according to Aschebrook, a ~30% discount to the company’s value. It’s honestly a genius move by G Squared. Venture funds typically have ~10 years to return capital to investors. A fund approaching the end of its life cycle with a lot of capital still tied up in private companies needs to sell, and there aren’t too many buyers in the secondary market for venture shares, so G Squared can effectively name their price. If, for example, there was a hot startup that was last valued at $5 billion, and it has a good chance of exiting via IPO or acquisition in the next few years, but some of its investors need capital, G Squared can now go in and say, “Hey, we’ll buy your stake at a $3.5 billion valuation,” and they have another ~10 years before they have to sell.

Basically, they’ve created their own stock market for private companies where they are one of the only buyers, and when you’re the only buyer in a market of desperate sellers, you can set the price. I suspect we’ll see more of these “secondary” funds emerge over the next couple of years.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.